Literature DB >> 20550546

Effect of an immunotoxin to folate receptor beta on bleomycin-induced experimental pulmonary fibrosis.

T Nagai1, M Tanaka, K Hasui, H Shirahama, S Kitajima, S Yonezawa, B Xu, T Matsuyama.   

Abstract

It has been suggested that alveolar and interstitial macrophages play a key role in the pathogenesis of idiopathic pulmonary fibrosis (IPF) by producing proinflammatory and/or fibrogenic cytokines. We showed that inflammatory macrophages expressed folate receptor beta (FRbeta) while resident macrophages in normal tissues expressed no or low levels of FRbeta. In the present study, we examined the distribution of FRbeta-expressing macrophages in the lungs of patients with usual idiopathic pulmonary fibrosis (UIP) and mice with bleomycin-induced pulmonary fibrosis (PF) and tested whether the depletion of FRbeta-expressing macrophages could suppress bleomycin-induced PF in mice. Immunostaining with anti-human or -mouse FRbeta monoclonal antibody (mAb) revealed that FRbeta-expressing macrophages were present predominantly in fibrotic areas of the lungs of patients with UIP and mice with bleomycin-induced PF. Intranasal administration of a recombinant immunotoxin, consisting of immunoglobulin heavy and light chain Fv portions of an anti-mouse FRbeta mAb and truncated Pseudomonas exotoxin A, increased survival significantly and reduced levels of total hydroxyproline and fibrosis in bleomycin-induced PF. In immunohistochemical analysis, decreased numbers of tumour necrosis factor-alpha-, chemokines CCL2- and CCL12-producing cells were observed in the immunotoxin-treated group. These findings suggest a pathogenic role of FRbeta-expressing macrophages in IPF. Thus, targeting FRbeta-expressing macrophages may be a promising treatment of IPF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20550546      PMCID: PMC2909418          DOI: 10.1111/j.1365-2249.2010.04182.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   5.732


  41 in total

Review 1.  From immunotoxins to immunoRNases.

Authors:  Claudia De Lorenzo; Giuseppe D'Alessio
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

2.  ICAM-1 and CD11b inhibition worsen outcome in rats with E. coli pneumonia.

Authors:  F Zeni; C Parent; R Correa; C Natanson; B Freeman; J Fontana; M Quezado; R L Danner; Y Fitz; S Richmond; E Gerstenberger; S M Banks; P Q Eichacker
Journal:  J Appl Physiol (1985)       Date:  1999-07

3.  Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia.

Authors:  Edwin Roger Parra; Ronaldo Adib Kairalla; Carlos Roberto Ribeiro de Carvalho; Esmeralda Eher; Vera Luiza Capelozzi
Journal:  Respiration       Date:  2006-11-14       Impact factor: 3.580

Review 4.  Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis.

Authors:  Eric S White; Michael H Lazar; Victor J Thannickal
Journal:  J Pathol       Date:  2003-11       Impact factor: 7.996

5.  A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages.

Authors:  Wei Xia; Andrew R Hilgenbrink; Eric L Matteson; Michael B Lockwood; Ji-Xin Cheng; Philip S Low
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

Review 6.  Cellular and molecular mechanisms of fibrosis.

Authors:  T A Wynn
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

7.  The C10/CCL6 chemokine and CCR1 play critical roles in the pathogenesis of IL-13-induced inflammation and remodeling.

Authors:  Bing Ma; Zhou Zhu; Robert J Homer; Craig Gerard; Robert Strieter; Jack A Elias
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

8.  Effective treatment of the pulmonary fibrosis elicited in mice by bleomycin or silica with anti-CD-11 antibodies.

Authors:  P F Piguet; H Rosen; C Vesin; G E Grau
Journal:  Am Rev Respir Dis       Date:  1993-02

9.  High serum levels of thrombospondin-1 in patients with idiopathic interstitial pneumonia.

Authors:  Mioko Ide; Hiroshi Ishii; Hiroshi Mukae; Atsuko Iwata; Noriho Sakamoto; Jun-ichi Kadota; Shigeru Kohno
Journal:  Respir Med       Date:  2008-07-21       Impact factor: 3.415

10.  Effectiveness of anti-folate receptor beta antibody conjugated with truncated Pseudomonas exotoxin in the targeting of rheumatoid arthritis synovial macrophages.

Authors:  Ryusaku Nagayoshi; Taku Nagai; Kakushi Matsushita; Katsuaki Sato; Nobuhiko Sunahara; Takemasa Matsuda; Tadashi Nakamura; Setsuro Komiya; Masanori Onda; Takami Matsuyama
Journal:  Arthritis Rheum       Date:  2005-09
View more
  14 in total

1.  Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus.

Authors:  Yingjuan Lu; Nikki Parker; Paul J Kleindl; Vicky A Cross; Kristin Wollak; Elaine Westrick; Torian W Stinnette; Mark A Gehrke; Kevin Wang; Hari Krishna R Santhapuram; Fei You; Spencer J Hahn; Jeremy F Vaughn; Patrick J Klein; Iontcho R Vlahov; Philip S Low; Christopher P Leamon
Journal:  Mol Med       Date:  2015-07-08       Impact factor: 6.354

Review 2.  Genetically manipulated mouse models of lung disease: potential and pitfalls.

Authors:  Rebecca M Baron; Alexander J S Choi; Caroline A Owen; Augustine M K Choi
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-23       Impact factor: 5.464

3.  Molecular imaging of folate receptor β-positive macrophages during acute lung inflammation.

Authors:  Wei Han; Rinat Zaynagetdinov; Fiona E Yull; Vasiliy V Polosukhin; Linda A Gleaves; Harikrishna Tanjore; Lisa R Young; Todd E Peterson; H Charles Manning; Lawrence S Prince; Timothy S Blackwell
Journal:  Am J Respir Cell Mol Biol       Date:  2015-07       Impact factor: 6.914

4.  Targeted delivery of mPGES-1 inhibitors to macrophages via the folate receptor-β for inflammatory pain.

Authors:  Liudmila L Mazaleuskaya; Seokwoo Lee; Hu Meng; Jeffrey D Winkler; Garret A FitzGerald
Journal:  Bioorg Med Chem Lett       Date:  2021-08-12       Impact factor: 2.940

5.  Airspace Macrophages and Monocytes Exist in Transcriptionally Distinct Subsets in Healthy Adults.

Authors:  Kara J Mould; Camille M Moore; Shannon A McManus; Alexandra L McCubbrey; Jazalle D McClendon; Christine L Griesmer; Peter M Henson; William J Janssen
Journal:  Am J Respir Crit Care Med       Date:  2021-04-15       Impact factor: 21.405

Review 6.  Advances in targeting the folate receptor in the treatment/imaging of cancers.

Authors:  Marcos Fernández; Faiza Javaid; Vijay Chudasama
Journal:  Chem Sci       Date:  2017-12-18       Impact factor: 9.825

7.  Folate receptor: a macrophage "achilles' heel"?

Authors:  Ingo Hilgendorf; Filip K Swirski
Journal:  J Am Heart Assoc       Date:  2012-08-24       Impact factor: 5.501

Review 8.  Macrophage heterogeneity in respiratory diseases.

Authors:  Carian E Boorsma; Christina Draijer; Barbro N Melgert
Journal:  Mediators Inflamm       Date:  2013-02-27       Impact factor: 4.711

9.  Novel Therapy for Atherosclerosis Using Recombinant Immunotoxin Against Folate Receptor β-Expressing Macrophages.

Authors:  Yuko Furusho; Masaaki Miyata; Takami Matsuyama; Taku Nagai; Hua Li; Yuichi Akasaki; Narisato Hamada; Takahiro Miyauchi; Yoshiyuki Ikeda; Takahiro Shirasawa; Kanako Ide; Chuwa Tei
Journal:  J Am Heart Assoc       Date:  2012-08-24       Impact factor: 5.501

10.  IL-13 signaling via IL-13Rα2 triggers TGF-β1-dependent allograft fibrosis.

Authors:  Stefan M Brunner; Gabriela Schiechl; Rebecca Kesselring; Maria Martin; Saidou Balam; Hans J Schlitt; Edward K Geissler; Stefan Fichtner-Feigl
Journal:  Transplant Res       Date:  2013-10-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.